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Abstract 
Maternal asthma represents a significant burden to individuals and the healthcare system, 
affecting 1 in 10 pregnancies worldwide. Approximately 50% of asthmatic women 
experience a deterioration of asthma control at some stage during pregnancy, with a number 
requiring use of oral corticosteroids for the management of acute exacerbations. The presence 
of maternal asthma and exacerbations during pregnancy is a noted risk factor for a range of 
adverse perinatal outcomes including preterm birth, small-for-gestational age, pre-eclampsia, 
and gestational diabetes. These negative impacts highlight the need for evidence-based 
approaches for improving asthma management during pregnancy and subsequent perinatal 
outcomes. Despite this, relatively small progress has been made in enhancing the 
AC
CE
PT
ED
 M
AN
US
CR
IPT
2 
 
management of maternal asthma in the clinical setting. A major challenge in improving 
outcomes of asthmatic pregnancies is that there is no single simplified approach for 
improving outcomes, but rather the requirement to consider the dynamic relationship between 
a myriad of interrelated factors that ultimately determine an individual’s ability to maintain 
adequate asthma control. Understanding how these factors are impacted by pregnancy and 
how they can be addressed through various interventions is therefore important in optimizing 
health outcomes. This review summarises key factors involved in influencing outcomes 
associated with maternal asthma. This includes an overview of the use of asthma medications 
in pregnancy, while also considering the impacts of interrelated aspects such as medication 
adherence, health-seeking behaviours, biological and lifestyle factors, co-morbidities, and 
asthma self-management strategies on asthma control. Addressing such factors through 
multidisciplinary approaches towards treatment have potential to improve the health of 
mothers and their offspring. Optimising asthma control should be a high priority within the 
antenatal setting, with women advised about the importance of good asthma control, 
managing asthma actively throughout pregnancy by utilising their asthma medications, and 
managing exacerbations in a timely and effective manner. 
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LRTA, leukotriene receptor antagonist 
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1. Introduction 
Maternal asthma represents a significant burden to individuals and the healthcare system. 
Asthma is one of the most common chronic medical conditions in pregnancy, complicating an 
estimated 8-13% of pregnancies worldwide.[1] There is clear evidence that maternal asthma is 
associated with significant perinatal morbidity and mortality, with 20-50% increased risk of 
adverse perinatal outcomes including low birth weight, small-for-gestational age, preterm 
birth, pre-eclampsia, and gestational diabetes.[2, 3] Given the increased risk of adverse 
pregnancy outcomes, it is perhaps not unsurprising that maternal asthma has also been 
associated with long-term adverse effects on the health of the offspring, including an increased 
risk of a wide spectrum of non-communicable diseases in the offspring.[4] 
These negative impacts highlight the need for evidence-based approaches for improving 
asthma management during pregnancy and subsequent perinatal outcomes. Despite this, only 
relatively small progress has been made in enhancing the management of maternal asthma in 
the clinical setting. A major challenge in improving outcomes of asthmatic pregnancies is that 
there is no single simplified approach for improving outcomes, but rather the requirement to 
consider the dynamic relationship between a myriad of interrelated factors that ultimately 
determine an individual’s ability to maintain adequate asthma control.  
Understanding how these factors are impacted on by pregnancy and how they can be 
addressed through various interventions is therefore important in optimizing health outcomes. 
For this reason, in this review we have chosen to provide an overview of what we believe to be 
some of key factors involved in influencing outcomes associated with maternal asthma. This 
involves looking beyond asthma medications and considering interrelated aspects such as 
health-seeking behaviours, asthma self-management, medication adherence, biological and 
lifestyle factors and co-morbidities. A description of the etiology, pathogenesis, and typical 
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management of asthma in general adults is beyond the scope of this review and can be found 
elsewhere.[5] 
2. Overview of asthma treatment in pregnancy 
The determination of safety of asthma medications in pregnancy is largely limited to 
observational studies, limiting the ability to precisely distinguish the impacts of asthma 
treatments from those of maternal asthma. Despite this challenge, there is a growing body of 
literature supporting the safety of various asthma medications during pregnancy, with a 
prevailing belief that uncontrolled asthma during pregnancy poses greater short and long-
term risk to the mother and her baby. A summary of asthma medications with respect to their 
usual doses, adverse events, and safety during pregnancy is presented in Table 1. The greatest 
amount of evidence exists for the use of inhaled corticosteroids in pregnancy, but there is 
increasing evidence to support the use of ICS combined with LABA.[6] Therefore there is no 
reason that women who enter pregnancy on a combined ICS + LABA should necessarily be 
switched to an ICS alone preparation. Existing recommendations are that asthma be managed 
during pregnancy in the same manner as a non-pregnant adult, including management of 
asthma medications.[7] This means selecting medication and delivery devices that meet 
patient’s needs and circumstances, with therapy divided into the use of long-term control 
medications to prevent asthma manifestations and the use of rescue therapy to provide 
immediate relief of symptoms. In accordance with non-pregnant adults, asthma control 
should be regularly assessed and preventer medications adjusted accordingly at regular 
intervals to maintain adequate symptom control. An approach towards the adjustment of 
asthma therapies in pregnancy is outlined in Figure 2. Given the high prevalence of poor 
medication adherence in pregnancy, it is critical that this aspect is evaluated prior to any 
recommendations to step up treatment. Further, among non-pregnant adults there is a general 
recommendation to consider stepping down therapy in situations where asthma is stable and 
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has been well controlled for 2-3 months, but evidence to support this strategy in pregnancy is 
very limited. Therefore consideration to stepping down treatment should only be considered 
if the woman is taking an inappropriately high dose of a medicine and should be done under 
careful supervision. 
3. Course of asthma in pregnancy 
Pregnancy is recognized as a major challenge in the management of asthma as it can alter 
the course of asthma severity and its treatment, which in turn has the potential to influence 
pregnancy outcomes. Recent data demonstrates that half of all women experience a loss of 
asthma control during pregnancy, with approximately 1 in 5 experiencing a moderate to 
severe exacerbation.[8] Explanations for this clinical observation are unclear, but could relate 
to a range of interconnecting factors, as outlined in Figure 1. Outside of pregnancy, it is well 
recognised that a number of factors impact on asthma control. Each of these factors in turn 
can be influenced by pregnancy, providing some explanation for changes in asthma control. 
For example, pregnancy is a time of significant change, including physiological, behavioural, 
and biological, with women interacting with the healthcare system with significantly greater 
frequency than they likely did prior to pregnancy. The impact of each of these factors on 
asthma management is outlined below. 
3.1.Medication adherence  
While the continuation of usual asthma medications during pregnancy is recommended in 
clinical guidelines, it is not uncommon for women to cease their asthma medications, with or 
without consultation with healthcare professionals.[9] This is of significant concern given that 
non-adherence to medication has been identified as a key factor involved in worsening asthma 
during pregnancy.[10] Decisions regarding the cessation of asthma medications during 
pregnancy may be driven through a perceived lack of benefit in continuing medications, 
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insufficient support and education from healthcare professionals regarding the use of asthma 
medications during pregnancy, or concerns regarding the safety of asthma medications during 
pregnancy.[11] In the prospective cohort study by Murphy et al. 40% of women reported non-
adherence to inhaled corticosteroids. [12] Reduced medication adherence to short-acting beta-
agonists may also be a concern in pregnancy, but data relating to the potential extent of this 
problem are not available. 
3.2 Healthcare provider interaction 
Generally speaking, pregnancy presents an opportunity for women to interact with the 
healthcare system at a greater frequency than they would have previously. Increased 
interaction with healthcare providers means increased opportunity to evaluate and advise on 
asthma control. However, this relies on the healthcare provider’s awareness of the importance 
of optimal asthma management during pregnancy and their training on how to educate and 
support pregnant women. A recent Australian survey of general practitioners highlight a 
significant lack of confidence or knowledge regarding the management of asthma during 
pregnancy.[13] Among survey respondents, a quarter (25.8%) indicated that they would 
advise pregnant women to decrease or discontinue asthma medications. Inadequate 
management practices also extend to the hospital setting, with a previous prospective cohort 
study demonstrating that despite presenting to the emergency department with similar asthma 
severity, compared to non-pregnant women, pregnant women were less likely to be treated 
with oral corticosteroids and experienced a 2.9 (95%CI 1.2-6.8) times greater likelihood of 
reporting an ongoing exacerbation two weeks later.[14] Such findings are not unique to 
medical practitioners, with a recent study involving midwives identifying feelings of 
uncertainty and a lack of confidence in antenatal asthma management.[15] Notably, 
midwives who reported having greater knowledge in asthma management also reported 
playing a greater role in antenatal asthma management. These studies highlight the 
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importance of education programs targeting healthcare professionals involved in the 
provision of antenatal care and having integrated systems in place to ensure pregnant women 
with asthma receive the additional support and care they require. 
3.3 Physiological and Biological changes 
Pregnancy is a time of significant physiological change, with marked changes in 
kidney, liver, cardiovascular, respiratory and immunological function orchestrated by 
alterations in the endocrine system and the release of various hormones and growth factors 
into the maternal circulation by the placenta.[16] Such adaptations aim to provide an optimal 
environment for the fetus to grow and develop, yet data suggests asthma may worsen in 
pregnancy due to these physiological adaptations. Immunological adaptations are the most 
studied and likely factors contributing towards worsening asthma control in pregnancy. 
Pregnancy induced changes in immune function may promote worsening of asthma control 
via the activation of chemokine pathways and increased circulating levels of monocytes and 
neutrophils (Osei-Kumah et al 2005, 2008. 2009).[17, 18]  Furthermore there is increasing 
evidence of several sex-specific strategies by which the fetus copes with presence of maternal 
asthma in utero.[19] These adaptations have recognised importance for the management of 
maternal asthma during pregnancy.  
Fetal sex has been implicated as a risk factor for worsening asthma in pregnancy, with 
pregnant women carrying a female fetus having poorer asthma control compared to women 
carrying a male fetus.[20] While the exact mechanism linking fetal sex with maternal asthma 
control remains uncertain, it is hypothesised that it may occur through sex specific 
differences in placental function that differentially influence maternal physiology and the 
course of maternal asthma in pregnancy. The sex specific differences in placental function in 
pregnancies complicated by asthma may also influence neonatal outcomes. Some of these 
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differences could be due to noted sex-specific differences in placental growth, development 
and function, including nutrient transport, energy metabolism, and endocrine function.[21] A 
large body of data has demonstrated that male and female placentae adapt differently to the 
presence of maternal asthma by adjusting placental sensitivity to endogenous glucocorticoids 
and affecting placental glucocorticoid regulated pathways that are central to fetal growth and 
development.[22] In short, males induce a state of glucocorticoid resistance in response to 
maternal asthma in order to continue to grow in an adverse environment. This adaptation 
poses a significant risk in presence of an acute asthma exacerbation with males more likely to 
deliver preterm, be growth restricted or stillborn. Females remain sensitive to the effects of 
glucocorticoids which result in reduced growth but a greater chance of surviving to term if 
mothers exacerbate.[22] Most importantly, the control of maternal asthma with ICS is 
protective against these sex specific effects and both and male and female fetuses grow 
normally when asthma is controlled and outcomes are comparable to a non-asthmatic 
population.[23] These data suggest fetal sex may pose a challenge not only in influencing the 
course of asthma during pregnancy, but also in influencing its impact on subsequent 
pregnancy outcomes. Given evidence that the course of pregnancy and its associated adverse 
impacts may be influenced by fetal sex, this highlights that subsequent investigation of 
interventions aimed at improving perinatal outcomes should consider fetal sex in their 
evaluation.  
The previously outlined physiological changes that occur during pregnancy can also 
introduce challenges in the assessment of asthma, with pregnancy-related factors such as 
dyspnoea of pregnancy, which can occur in up to 70% of pregnancy women, potentially 
confused with asthma-related symptoms.[6] Theoretically, hormonal, metabolic, and 
physiological changes during pregnancy could alter the mechanics of breathing and 
pulmonary function in pregnant women which may change across the duration of pregnancy, 
AC
CE
PT
ED
 M
AN
US
CR
IPT
9 
 
but evidence relating to the magnitude and significance of such changes is unclear and often 
inconsistent.[24] Therefore, at this stage the general recommendations are that lung function 
can be assessed and monitored as for non-pregnant adults, with the exception of methacholine 
challenge testing which is not recommended during pregnancy.[6] Beyond direct evaluation 
of pulmonary function, there are a range of tools available for evaluating asthma control in 
adults, but concerns regarding their applicability and validity for use in pregnancy have been 
raised due to challenges related to attributing symptoms to pregnancy or underlying 
asthma.[25] Most recently, however, a modified version of the Asthma Control Test, where 
additional focus is placed on identifying shortness of breath due to asthma rather than 
dyspnoea of pregnancy, has been demonstrated as being reliable and valid for evaluating 
asthma control in pregnancy.[25]  
3.4 Lifestyle changes 
Pregnancy is a time when women commonly enact a range of positive behavioural changes, 
frequently out of desire to improve outcomes of their unborn child and often with the support 
and encouragement of antenatal care providers. Examples of such include reduction or 
cessation of cigarette use or changes in diet and exercise.  
Smoking cessation in particularly has been a major focus of educational programs offered 
within antenatal care settings. Given the associated harmful impacts of smoking on asthma 
control, interventions focused on smoking cessation among asthmatic women are likely to be 
even more effective in improving health outcomes.[26] How these benefits are obtained, 
however, requires greater attention. According to data from a prospective cohort study of 
asthmatic women, 29% of smokers ceased smoking during early pregnancy through usual 
antenatal care support mechanisms.[27] In contrast, among those who received additional 
support through a nurse-led antenatal asthma management program, 54% stopped smoking in 
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early pregnancy. Therefore, the impact of various smoking cessation strategies may vary 
dramatically in terms of how they operate and target individuals, but should remain a key 
focus for improving perinatal outcomes in asthmatic pregnancies.  
Maternal diet represents another area where changes commonly occur during pregnancy.[28] 
These changes include alterations in consumption (both increases and decreases) of certain 
foods (e.g. reduction in foods at risk of listeria or mercury contamination, increase in healthy 
foods such as fruit) as well as general increases in dietary supplement intake (e.g. folate, 
vitamin D, omega 3 fatty acids, iodine, multivitamins).[29] Such changes in dietary intakes 
could have important implications for alterations in asthma control during pregnancy. Some 
of these changes have been hypothesised to occur through alterations in oxidative stress.[30] 
Dietary intervention studies among non-pregnant adults have demonstrated protective 
impacts of antioxidants in asthma, but no such studies have been undertaken in 
pregnancy.[30] Observational data are available, however, to support such an intervention, 
with evidence that pregnant women with moderate to severe asthma have altered circulating 
concentrations of antioxidants compared to women with mild or no asthma, whereas low 
antioxidant concentrations were associated with reduced fetal growth among asthmatic 
pregnancies.[31] In addition, while the impact of dietary patterns has not been extensively 
explored in pregnancy, pre-conception intake of a high fat/sugar/takeaway diet has been 
associated with an increased likelihood of uncontrolled asthma during pregnancy.[32]   
Lastly, interventions aimed at improving exercise in pregnancy have demonstrated positive 
effects in reducing the risk of excessive gestation weight gain and risk of adverse pregnancy 
complications.[33] While data on the impacts of such exercise interventions on asthma 
control in pregnancy are absent, a recent randomized controlled trial in non-pregnant obese 
adults demonstrated that the addition of exercise to a short-term weight-loss program led to 
significant improvements in asthma control and anti-inflammatory biomarkers, as well as 
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reductions in airway and systemic inflammation.[34] Therefore, further research to identify 
whether dietary and exercise interventions can improve asthma control in pregnancy are 
warranted.  
3.5. Co-morbidities 
Comorbidities are common and are being increasingly recognized as playing an 
important role in influencing outcomes in individuals with asthma. Such common 
comorbidities include gastro-esophageal reflux disease, mental illness, obesity, and allergic 
rhinitis. While some of these factors may not appear immediately modifiable, especially 
within an obstetric setting, awareness of the contribution of these factors to impaired asthma 
control is important. Just as concerns regarding medication safety can impact on adherence to 
asthma medications during pregnancy, they could also have the same effect on medications 
used in the management of other co-morbidities. Clinicians should be aware of the increased 
likelihood of these co-morbidities among women with asthma and the requirement for 
comprehensive assessment, treatment, or referral as appropriate. 
Rhinitis is perhaps one of the most common co-morbidities. In a recent prospective 
clinical trial, rhinitis occurred in 65% of pregnant asthmatic women , with 20% of women 
experiencing rhinitis only during pregnancy.[35] While rhinitis symptoms improved as 
pregnancy progressed, the presence of rhinitis was associated with poorer asthma control and 
anxiety. Further, atopic rhinitis was associated with poorer lung function. A separate study in 
the same cohort of women identified a higher prevalence of asthma exacerbations among 
women who were overweight (51%) or obese (48%) compared with healthy weight women 
(25%; P=0.026).[36] Pregnancy related weight gain appeared to have no impact on 
exacerbation risk.[36] Further investigations revealed that maternal overweight or obesity 
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was associated with altered macrophage activation and that altered macrophage activation 
was associated with an increased risk of exacerbations requiring oral corticosteroids.[36]  
A prospective cohort study undertaken within a socially disadvantaged population in 
Australia identified that women with a self-reported history of depression or anxiety were 
much more likely to experience poor asthma control during pregnancy.[37] These findings 
are supported by those of two previous studies which identified that anxiety was an 
independent risk factor for poor asthma control and exacerbations.[38, 39] Further, women’s 
perception of asthma control in early pregnancy reduced the risk of subsequent 
exacerbations.[39]  It is unclear whether these associations are reflective of behavioural, 
social, or biological factors or the combination of all three associated with the presence of a 
mental health illness. What evidence it does provide, however, is the identification of a group 
of higher risk  women who are already recognised at being at increased risk of adverse 
perinatal outcomes and so could benefit from additional attention and support. Strategies 
aimed at addressing such key psychosocial factors, such as reducing treatment-related 
anxiety, may help improve asthma control and related pregnancy outcomes.  
4. Interventions for improving asthma management in pregnancy 
An improved understanding of the unique interplay between pregnancy and asthma has led to 
the investigation of strategies aimed at improving asthma related outcomes. While a number 
of different interventions have been trialed, including self-management education, and 
individualized asthma management plans according to airway inflammation status, there is a 
lack of data associating these interventions with improvements in perinatal outcomes.[40]  
4.1 Asthma Education and Self-Management Skills 
Self-management programs are designed to facilitate the acquisition of preventive or 
therapeutic health care activities by patients through the provision of education by healthcare 
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professionals which in turn assists in the adoption of health-promoting behaviours.[41] A 
number of studies have investigated the impact of providing asthma self-management 
education in pregnancy on asthma related outcomes.[12, 27, 42, 43] These services 
incorporate education, self-monitoring, regular review with optimisation of pharmacotherapy, 
and written asthma action plans for management of unstable asthma. In one prospective non-
comparative study, pregnant women were identified as having high levels of non-adherence, 
inadequate knowledge of asthma inhaler technique, and insufficient knowledge of asthma 
management strategies.[12] Further, less than 20% of women reported having an asthma 
action plan to assist them in the management of exacerbations during pregnancy.[12] The 
intervention itself was effective in improving skills and knowledge about asthma during 
pregnancy. A more recent prospective before-after study reported on the impact of the 
introduction of a nurse-led antenatal asthma management service on asthma related outcomes 
during pregnancy.[27] The introduction of this service was associated with a reduction in loss 
of control (RR 0.67; 95%CI 0.46-0.99), persistent uncontrolled asthma (RR 0.48; 95%CI 
0.26-0.90), and asthma exacerbations (RR 0.69; 95%CI 0.33-1.42).[27] The prevalence of 
exacerbations reduced from 19.1% to 15% (p=0.48) following the intervention. The most 
robust evidence for the impact of antenatal asthma self-management education comes from a 
recent Australian randomised controlled trial. This involved randomisation of 60 women with 
asthma at less than 20 week’s gestation to receive either usual care or a pharmacist-led 
asthma management intervention. The intervention consisted of multidisciplinary care, 
education and regular monthly monitoring throughout pregnancy and was associated with a 
subsequent reduction in asthma control questionnaire (ACQ) scores at 3 months (-0.22 
95%CI: -0.54, 0.10) and 6 months (-0.60 95%CI -0.85, -0.36) compared to those receiving 
usual care.[42] Notably, no women in either group reported experiencing any exacerbations 
during the study, despite the noted differences in asthma control.  
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Awareness of the benefits of improved asthma control through regular self-monitoring of 
symptoms and self-management according to a written asthma action plan led to the trial of a 
telehealth based intervention in pregnant asthmatics.[43] In this study the use of a mobile 
smartphone based application, which utilised a handheld respiratory device to support women 
in regularly monitoring their asthma and provided advice on how to management a 
deterioration in symptoms, was effective in improving asthma control over a 6-month follow-
up period.[43] The major benefit of such an approach was that it removed the necessity for 
face-to-face visits and removing such barriers to care, with data on asthma symptoms 
electronically communicated to treating healthcare professionals enabling intervention where 
necessary. Importantly, while improvements in asthma control were identified across these 
studies, there was no evidence of associated improvements in perinatal outcomes.  
4.2. Individualisation of asthma treatments 
In recent years there has been growing interest in the identification and examination 
of differing asthma phenotypes.[44] The identification of such phenotypes has offered 
promise for the potential identification of those more likely to respond to a particular 
treatment or management strategy. There exists a number of examples demonstrating the 
success of such an approach.  
For example, the presence of airway eosinophilia (which is associated with an inflammatory 
phenotype) is associated with more favourable response to corticosteroid therapy,[45-47] and 
a greater risk of exacerbations when corticosteroids are withdrawn.[48] In contrast, 
administration of ICS to individuals with non-eosinophilic asthma has been associated with a 
significantly poorer response to treatment and an increased likelihood of poor response to 
inhaled corticosteroids. [45, 46] 
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Such findings have stimulated interest in the identification of airway inflammation and its use 
as a tool to better guide asthma treatments. This approach was applied in pregnancy in the 
Managing Asthma in Pregnancy (MAP) study, which utilised the fraction of exhaled nitric 
oxide (FENO) and asthma symptoms to guide treatment decisions.[49] The use of this novel 
non-invasive approach was associated with a substantial reduction in the prevalence (41% vs. 
25%; p=0.011) and incidence (incidence rate ratio 0.50, 95% CI 0.33–0.76; p=0.001) of 
women experiencing exacerbations during pregnancy.[49] A reduction in neonatal 
hospitalisations was also observed (n=8 [8%] vs 18 [17%]; p=0.046), but the study was 
specifically powered to look at perinatal outcomes. This, however, is the focus of a larger 
ongoing study which will recruit a much larger number of women and focus on whether this 
approach leads to improvements in perinatal health outcomes.[50] This ongoing study will 
also include women who smoke, which will address an important limitation from the 
previous study as smokers were excluded. Given the high proportion of asthmatic women 
who also smoke during pregnancy (>20%),[26] examining efficacy of this intervention 
among these women is important to guide clinical practice. Notably, use of FENO to guide 
asthma treatment is not a stand-alone approach and does not replace the need for appropriate 
asthma self-management education.  
4.3. Additional considerations for asthma management in pregnancy 
4.3.1. Optimal target for improving outcomes of asthmatic pregnancies 
While significant focus lies on improving asthma control during pregnancy, how asthma 
control is evaluated and defined remains a significant challenge for clinical practice and in 
clinical trials. Tools such as the ACQ or asthma control test (ACT) are commonly utilised in 
the evaluation of asthma control at a specific point in time,[25, 51] but there is an absence of 
tools available for evaluating asthma exacerbations.[52, 53] Asthma exacerbations are rather 
commonly classified based on specific events, such as requirement for hospital admission, 
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emergency department presentation, unscheduled doctor visits, or receipt of oral 
corticosteroid course. The concern lies in how well such events reflect asthma control 
throughout pregnancy.[54] For example, women with poor self-awareness may not even 
recognise that their asthma control is deteriorating and may therefore not seek additional 
help, while the opposite may be true for those with greater self-awareness who may seek help 
much earlier. Therefore, while the presence of an asthma exacerbation during pregnancy has 
been associated with increased risks of adverse perinatal outcomes, data are limited on the 
relative impact of asthma control evaluated independently of asthma exacerbations.[54] 
Exacerbations identified during pregnancy likely reflect a surrogate marker for uncontrolled 
asthma during pregnancy, but their relative predictive value in identifying women with 
persistently poorly controlled asthma during pregnancy may be altered by the characteristics 
of the population being studied. The requirement for greater focus on asthma control comes 
from recent findings of a prospective cohort study undertaken among a socially 
disadvantaged population, where asthma control, but not exacerbations, were associated with 
adverse perinatal outcomes.[8] When directly assessed in the clinical setting, many women 
were identified as having persistent uncontrolled asthma which could be considered a current 
exacerbation, but they had a lack of self-awareness to identify the extent of their symptoms or 
had simply ignored them. Such observations raise the possibility that direct evaluation of 
asthma control may have greater validity in predicting subsequent pregnancy outcomes than 
just exacerbations reported alone, but this remains to be determined.  
4.3.2. Timing of interventions in pregnancy 
The delay between the actual beginning of pregnancy, i.e. the time that women find out that 
they are pregnant to the time at which they begin to receive antenatal care, represents a likely 
challenge for improving perinatal outcomes in asthmatic pregnancies. The reality is that 
insufficient data are available to determine which periods of pregnancy are critical for 
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optimised asthma control to reduce the risk of adverse outcomes. There is the potential that 
adverse outcomes could differ according to uncontrolled asthma in early pregnancy versus later 
pregnancy, highlighting an important area for future research. Such evidence would help 
identify critical periods of pregnancy to intervene to improve health outcomes. Currently, 
intervention studies have included women up until 20 weeks’ gestation.[42, 49] While this may 
still be beneficial in improving asthma control in the second half of pregnancy, a recent 
prospective cohort study identified that 50% of asthma exacerbations occurred in women prior 
to 20 weeks’ gestation, [8] highlighting the potential importance of earlier intervention 
strategies. 
One approach lies in targeting asthma interventions as soon as women identify that they are 
pregnant, which may occur following an early visit to their GP for confirmation of pregnancy 
or antenatal booking appointment in the hospital, but for many this may still not occur until 
later into the second trimester. The other approach lies in ensuring initiatives are in place to 
encourage optimal asthma management among women of childbearing potential, such that they 
enter pregnancy in the best possible position. With previous research identifying that less than 
20% of women entered pregnancy with an established asthma action plan,[12] this represents 
a key objective for identifying improvements in pre-conception based initiatives. 
  
5. Conclusion 
Overall, pregnancy represents a significant opportunity to optimize asthma therapy and 
maximize lung function in order to reduce the risk of acute exacerbations and resultant adverse 
perinatal outcomes. However, despite knowledge of the harms associated with asthma during 
pregnancy little has been done to improve its management and reduce associated perinatal 
morbidity and mortality within the antenatal setting. This lack of progress is largely based on 
AC
CE
PT
ED
 M
AN
US
CR
IPT
18 
 
a lack of high-quality studies on the management of maternal asthma and where studies do 
exist, they typically focus on surrogate markers of maternal wellbeing, including asthma 
control and exacerbations. The assumption has been that improving maternal asthma control 
will in turn lead to improved perinatal health outcomes, but whether this is realistic is unclear 
and existing evidence does not support clear improvements in perinatal health outcomes 
associated with any maternal asthma management intervention.  
In the absence of such data to support specific interventions, it is important that maternal 
asthma is recognised within the antenatal setting as a contributing factor towards adverse 
pregnancy outcomes. This means that optimising asthma control should be a high priority 
within the antenatal setting, with women advised about the importance of good asthma 
control, managing asthma actively throughout pregnancy by utilising their asthma 
medications, and managing exacerbations in a timely and effective manner.  
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Figure 1. Interdependence of factors influencing asthma management with a focus on optimising asthma 
control during pregnancy 
  
Asthma 
Control 
Asthma Self-
Management 
Medication 
Adherence 
Co-morbidities 
Biological 
Factors 
Lifestyle 
Factors 
Health-
Seeking 
Behaviours 
Pregnancy 
Pregnancy 
AC
CE
PT
ED
 M
AN
US
CR
IPT
24 
 
 
Figure 2. Stepped approach to adjusting asthma preventer therapy during pregnancy* 
    ‼ 6 
High-dose ICS + LABA + oral corticosteroid      
    ↗ OR Omalizumab† ↘     
   ‼ 5 
High-dose ICS + LABA     
   ↗ OR Omalizumab† ↘    
  ‼ 4 
Medium-dose ICS + LABA    
  ↗ OR Medium-dose ICS + LRTA OR theophylline¤ ↘   
 ‼ 3 
Medium-dose ICS   
 ↗ OR Low-dose ICS + either LABA, LTRA OR theophylline¤ ↘  
‼ 2 Low-dose ICS  ↗ OR LRTA, theophylline¤  
1 None  
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LRTA, leukotriene receptor antagonist 
‼ Before stepping up, check symptoms are due to asthma, inhaler technique is correct, and adherence is 
adequate 
↗ Consider stepping up if good control is not achieved 
↘ The relative safety of stepping down in pregnancy has not been well studied and must be balanced against the 
potential harms of worsening asthma control. Consider stepping down only if the woman is taking an 
inappropriately high dose of a medicine.  
 
¤ Theophylline is a less desirable alternative during pregnancy due to need to monitor serum concentration levels 
and increased risk of adverse events 
† Restricted under specialist use for allergic asthma 
*Data modified from Schatz M, Dombrowski M. N Engl J Med 2009;360:1862-1869 
 
 
Table 1. Overview of medications used in the management of asthma during pregnancy[6, 55] 
Medication Usual Dose Safety Data in 
Pregnancy 
Inhaled bronchodilators   
Short-acting bronchodilators  Reassuring human data 
Salbutamol/albuterol 100-200 mcg when required 
Terbutaline 500-1500 mcg when required 
Long-acting bronchodilators¤  Limited experience; 
reassuring data 
available for salmeterol 
or eformoterol 
Salmeterol 25-50 mcg twice daily 
Eformoterol 6-12 mcg twice daily 
Vilanterol 25 mcg once daily 
Inhaled corticosteroids  Reassuring human 
data; beclomethasone, 
budesonide, or 
fluticasone propionate 
preferred due to greater 
experience 
Beclomethasone Low: 100-200 mcg/day 
Medium: >200-400 mcg/day 
High: >400 mcg/day 
Budesonide Low: 200-400 mcg/day 
Medium: >400-800 mcg/day 
High: >800 mcg/day 
Ciclesonide Low: 80-160 mcg/day 
Medium: >160-320 mcg/day 
High:>320 mcg/day 
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Fluticasone propionate Low: 100-200 mcg/day 
Medium: >200-500 mcg/day 
High: >500 mcg/day 
Systemic corticosteroids 
 
 Use of systematic 
corticosteroids 
associated with 
increased risk of oral 
cleft and adverse 
pregnancy outcomes 
(e.g. pre-eclampsia, 
preterm birth, small-
for-gestational age), 
but likely confounded 
by maternal asthma 
severity 
Prednisolone Exacerbation: 37.5-50 mg once daily for 
5-10 days 
Maintenance: Variable dose according 
to response 
Leukotriene receptor 
antagonist 
 Limited experience; 
reassuring human data 
available Montelukast 10 mg daily 
Zafirlukast 20 mg twice daily 
Other treatments   
Omalizumab 75-375 mg every 2-4 weeks 
(dose according to weight and serum 
total IgE level) 
Limited experience; 
reassuring human data 
Theophylline 400-600 mg/day  
(dose according to theophylline level) 
Reassuring human 
data; limited role in 
practice due to 
monitoring 
requirements and 
associated risk of 
toxicity 
¤ Some available individually and in combination with ICS; should not be used for monotherapy 
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